Euler's totient function

Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies

Retrieved on: 
Friday, December 2, 2022
Dai, Peptide, Focus X, Full Life Christian Centre, CADD, CMC, Cryogenic electron microscopy, PCC, Radiopharmaceutical, Trust, Chemical substance, IIT, Therapy, Cancer, Research, ASMS, CSO, HDX, EFS, Toxicity, DNA, Patient, Acquisition, Euler's totient function, SPR, Head, Control, CIO, Antibody, Drug, PDC, Pharmaceutical industry, Fine chemical, Manufacturing

They completed their angel round in the third quarter of 2020, which was led by Viva.

Key Points: 
  • They completed their angel round in the third quarter of 2020, which was led by Viva.
  • In addition to financial support, Viva also provided Focus-X with comprehensive incubation services to help it realize the transformation from "concept to product."
  • Viva provides efficient and high-quality screening and synthesis services for Focus-X with the help of its peptide research and development platform.
  • Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators.

Absci Reports Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, YouTube, Review, Protein, Investment, Doctor of Philosophy, Pharma, Acceleration, Nasdaq, File, Research, Merck, Technology, Synthetic biology, Board, Drug discovery, Securities Act of 1933, Meta, SEC, Total revenue, Antibody, Translation, Board of directors, U.S. Securities and Exchange Commission, Securities Exchange Act of 1934, Drug design, BioRxiv, Preprint, Drug development, Deep learning, Bayer, Growth, Social media, NEW, CEO, Drug Quality and Security Act, NSAA, Industry, Euler's totient function, FDA, Management, Pharmaceutical industry, Fine chemical, Video game, Bank, Facebook, AI

VANCOUVER, Wash. and NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today reported financial and operating results for the quarter ended September 30, 2022.

Key Points: 
  • VANCOUVER, Wash. and NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today reported financial and operating results for the quarter ended September30, 2022.
  • Total Revenue was $2.4 million for the third quarter of 2022, as compared to $1.5 million for the third quarter of 2021.
  • Research and development expenses were $15.5 million for the third quarter of 2022, as compared to $10.7 million for the third quarter of 2021.
  • Selling, general, and administrative expenses were $11.4 million for the third quarter of 2022, as compared to $9.7 million for the third quarter of 2021.

Absci Reports Second Quarter 2022 Financial Results and Business Update

Retrieved on: 
Thursday, August 11, 2022
People, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Synthetic biology, Drug discovery, CEO, GLOBE, Computational biology, NEW, Technology, AI, Growth, Securities Exchange Act of 1934, SEC, Investment, Research, Workforce, Public expenditure, Review, Euler's totient function, Twitter, Drug design, International Conference on Information Systems Security and Privacy, Deep learning, Internal, Translation, Social media, Securities Act of 1933, Protein, File, Nasdaq, Machine learning, LinkedIn, Conference, PEGS, Adoption, Medical device, Pharmaceutical industry, Fine chemical, Video game

VANCOUVER, Wash. and NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended June 30, 2022.

Key Points: 
  • Research and development expenses were $16.2 million for the second quarter of 2022, as compared to $11.0 million for the second quarter of 2021.
  • Selling, general, and administrative expenses were $10.5 million for the second quarter of 2022, as compared to $5.2 million for the second quarter of 2021.
  • Net loss was $28.7 million for the second quarter of 2022, as compared to $41.2 million for the second quarter of 2021.
  • Absci now expects a net decrease in cash, cash equivalents, and restricted cash of approximately $110 million for 2022.

Absci Reports First Quarter 2022 Financial and Operating Results

Retrieved on: 
Wednesday, May 11, 2022
Translation, Drug development, Investment, Drug design, File, Twitter, Nasdaq, U.S. Securities and Exchange Commission, Deep learning, GLOBE, Securities Exchange Act of 1934, Securities Act of 1933, Merck, Research, Drug discovery, Review, Drug Quality and Security Act, Synthetic biology, LinkedIn, Carnegie Hall Tower, SEC, NVIDIA, CEO, Protein, Technology, Growth, AI, Naturalness, Euler's totient function, Social media, Nature, Medical device, Cryptocurrency, Pharmaceutical industry, Video game

VANCOUVER, Wash., May 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended March31, 2022.

Key Points: 
  • VANCOUVER, Wash., May 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended March31, 2022.
  • Research and development expenses were $15.8million for the first quarter of 2022, as compared to $7.1million for the first quarter of 2021.
  • Selling, general, and administrative expenses were $10.9million for the first quarter of 2022, as compared to $4.7million for the first quarter of 2021.
  • Net loss was $29.5million for the first quarter of 2022, as compared to $11.0million for the first quarter of 2021.

Absci Reports Full Year 2021 Financial and Operating Results

Retrieved on: 
Tuesday, March 22, 2022
Microsoft, LinkedIn, Euler's totient function, Investment, Synthetic biology, NVIDIA, Board, Public expenditure, SEC, Research, CEO, CTO, Â, Review, Translation, Protein, Director, Twitter, U.S. Securities and Exchange Commission, Technology, Securities Act of 1933, Securities Exchange Act of 1934, Nasdaq, GLOBE, Drug discovery, Social media, AI, Deep learning, Merck, File, Medical device, Pharmaceutical industry, Animal, Lithium

Our progress this quarter capped off a remarkable year for Absci from start to finish, said Sean McClain, Founder and CEO.

Key Points: 
  • Our progress this quarter capped off a remarkable year for Absci from start to finish, said Sean McClain, Founder and CEO.
  • Successfully executed partnerships representing five Active Programs in 2021 and three of our projected eight new programs so far in 2022.
  • Revenue was $1.5 million for the three months ended December31, 2021 compared to $2.7 million for the three months ended December31, 2020.
  • For more information visit www.absci.com and follow us on social media: Twitter: @Abscibio, LinkedIn: @absci, and subscribe to our Absci YouTube channel .